Overactive Bladder Articles & Analysis
11 news found
BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of Overactive Bladder, today announced additions to its leadership team in preparation for commercialization of the RENOVA product line. ...
The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder (OAB) for patients with urinary urgency incontinence (UUI) symptoms. ...
“We believe that RENOVA’s minimally invasive and patient centric approach to the treatment of Overactive Bladder will meet the needs of many patients who are disappointed with existing therapies. ...
BlueWind Medical’s management will also be conducting individual meetings with investors on November 29th Additional information about Bluewind Medical can be found on their website. About Overactive Bladder: According to the American Urological Association, OAB is a chronic, debilitating condition affecting over 33 million Americans. ...
BlueWind Medical’s management will also be conducting individual meetings with investors on November 29th Additional information about Bluewind Medical can be found on their website. About Overactive Bladder: According to the American Urological Association, OAB is a chronic, debilitating condition affecting over 33 million Americans. ...
” added Lemaitre. About Overactive Bladder: According to the American Urological Association, OAB is a chronic, debilitating condition affecting over 33 million Americans. ...
The proceeds will fund the company’s SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB). Neuspera Medical Inc. is a medical device company that leverages both exclusively licensed and proprietary power transfer ...
He co-founded Axonics and has served in his current role for over seven years, during which time the company developed, obtained FDA approval for, and launched its sacral neuromodulation system to treat overactive bladder, acquired Bulkamid to treat stress urinary incontinence, and raised $138 million in its 2018 IPO plus $267 million through two subsequent ...
“BlueWind Medical has achieved significant milestones this year, including launching the pivotal OASIS Clinical Trial for overactive bladder and expanding our leadership team across quality, regulatory and clinical affairs. ...
Clinical investigators in the OverActive Bladder Stimulation System Study (OASIS) of the RENOVA iStim system, Drs. ...
S. sites in the Pivotal Clinical Trial of the RENOVA iStim™ implantable tibial neuromodulation System (RENOVA) for the treatment of Overactive Bladder (OAB) following conditional Investigative Device Exemption (IDE) approval by the U.S. ...